Trending Now

Key Takeaways from LFJ’s  Virtual Town Hall: PACCAR Revisited

By John Freund |

Key Takeaways from LFJ’s  Virtual Town Hall: PACCAR Revisited

On Thursday August 15th, LFJ hosted a Virtual Town Hall titled ‘PACCAR Revisited.’ The live event revisited the PACCAR decision one year later and explored what the future holds for legal funding in the UK and beyond.

Panelists included Ben Knowles (BK), Chair International Arbitration at Clyde & Co LLP, Robert Marven (RM), Barrister at 4 New Square, Nicholas Marler (NM), Head of Technical Underwriting at Litica Ltd, and Neil Purslow (NP), Founder and Chief Investment Officer, Therium Capital Management Limited. The panel discussion was moderated by Tets Ishikawa, Managing Director of LionFish Litigation Finance Limited.

Below are some key takeaways from the event:

We don’t hear much from insurers in regard to the PACCAR issue. Nicholas, from an insurer’s perspective, what are your thoughts?

NM: The ATE insurers’ odyssey through the world of PACCAR is in some ways quite different from that of a litigation funder. At first bluff, you might think that PACCAR doesn’t have anything to do with insurers because it has to do with litigation funding agreements, and you’d never catch an insurer signing an LFA, so what’s the problem?

If you scratch a little deeper though, the reality is quite different. If you as an insurer, insure a funder, and the funder gives an adverse costs indemnity to the claimant, then all of a sudden, the insurer’s contractual fortunes are tied to the funders. If the LFA is unenforceable, then not only can the insurer not collect its contingent premium if there’s a success, but the coverage provided to the funder has vanished–this is because the LFA is unenforceable.

We actually had this exact experience play out. An opportunistic claimant sought to cut the funder out, because it felt emboldened to do so as a result of the PACCAR decision. When they were informed that doing so would void their insurance, which was to their benefit, they magically found the goodwill necessary to resolve things with their funder and an amicable solution was quickly found.

You’ve touched on enforceability. Given how central that is to the heart of the PACCAR issue, Robert, can you share some insights and perspectives on this corse issue?

RM: There are essentially two views on the concept of enforceability. One is that it essentially says there isn’t anything wrong with the contract, just that it can’t be enforced. There is another view which says that the contract is unenforceable, that it is an illegal contract. I don’t agree with that. It seems this is one of the paradoxes of PACCAR, it seems to have rendered unenforceable funding agreements that were perfectly legal under common law.

A lack of enforceability is important to understand as a two-way street. It means the funder cannot enforce, and it also means the claimant cannot enforce. And this is the key to understanding why things have been put right in cases that are still ongoing. A claimant who says to a funder ‘I don’t have to pay you anymore,’ well, a funder could say to the same token, ‘I don’t have to fund your case anymore.’ And we have seen cases that have been over or very nearly over, where the claimants think they don’t need the funder anymore and saying ‘thank you very much, I needed the funding but I don’t have to pay you.’ Or ‘I did pay you, but I want the money back.’

This is where it’s important to remember that enforceability is a two-way street. If all sides want to continue to carry on, then everyone has an incentive in fixing the problem. It’s only where those interests converge that seem to have led to a significant litigation dispute.

Ben, from your perspective, how do you think this affects the UKs standing as a legal jurisdiction?

BK: PACCAR created a mess, and it was an expensive mess, irrespective of where we’re going to end up. There’s been a lot of lawyer’s time figuring out what PACCAR means and where we’re going to go. The PACCAR fix, as I call it, would have cleared things up to some extend. But the absence of that means some of this uncertainty will continue. And uncertainty means additional costs.

We have these various appeals on the funding agreements out there at the moment. I would expect that in some of these cases, there will be appeals that go to the Court of Appeals, and potentially, all the way up to the Supreme Court. My feeling is, when there’s a case to be funded, lawyers will find a way to get that case funded. Although I’d imagine there will be a risk premium attached to that funding, not least because everybody will be getting their funding agreements checked, double-checked and triple-checked. And you may have lawyers who disagree on what’s permissible, and that leads to additional costs at the start of the case.

This session is about PACCAR, but we’d be remiss not to talk about the CJC, given how the two issues merge. Neil, you’re on the consultation group for the CJC review. Are there any insights you’re able to share?

NP: There’s now a working party reporting up to the CJC. We’re expecting an interim report from that working party to come out in late summer or early autumn, and there will be a consultation, and then the final report in the middle of next year. So we’ve put on quite a tight timeline.

From an industry perspective, this review is welcome, unless you’re opposed to the idea of talking about regulation, which I don’t think the industry is. This is a sensible organizational group that is considering these points in a proper and thoughtful way. I would encourage people to get behind the work that ILFA and ALFA are doing here, and I’d also encourage funders to get involved in the consultation phase as well. It’s very important that the CJC are thinking about these points with a full and proper understanding of how funding actually works, so they can understand the impact.

I think it’s also important that the industry makes sure that the review takes place in a proper context, and by ‘proper context’ I mean that there is an understanding that funding does have benefits. So the review should look at how good responsible funding can be encouraged and those benefits can be maximized, rather than looking at funding as a suspicious thing that needs to be controlled and is just a risk. I think there is a very positive message for funding that needs to be emphasized, and I think the CJC needs to look at it through this positive lens, and I’m confident that they will.

To view the entire digital event, click here.

About the author

John Freund

John Freund

Commercial

View All

Chariot Claims Raises $10M Series A to Scale Mass Consumer Arbitration Claims

Chariot Claims has closed a $10 million Series A round to expand a platform that sources and pre-qualifies consumer claims for mass arbitration, bringing total funding to $15.7 million.

As reported by LawNext, the round was led by Silverton Partners, with general partner Mike Dodd participating, alongside Indicator Ventures, Lightbank, Neon Fund, ZVC, Rosecliff, Alumni Ventures, FJ Labs, Graph Ventures and Vermilion. The company previously raised a $3.6 million seed round led by Indicator Ventures in April 2025.

Founded in 2023 as ClaimClam and rebranded in 2025, the company is led by chief executive Zim Hang. It generates more than 200,000 pre-qualified claims a month across roughly 80 active corporate cases. Chariot Claims is not a law firm.

The business is built on a participation gap. Only about 4% of harmed consumers file claims, and the company reports that its users recover an average of roughly $460, compared with the $32 average identified in a Consumer Financial Protection Bureau analysis of class action distributions.

Proceeds will fund investment in artificial intelligence and expansion into children's data privacy, financial privacy and healthcare privacy claims, as well as defences against corporate retaliation. The company has more than doubled its headcount.

The raise reflects continued investor appetite for claim aggregation infrastructure, which sits adjacent to litigation finance and increasingly competes with it for the same consumer-facing claim volume.

Rugby Concussion Litigation Survives Collapse After Funder Covers £1.5m Costs Order

The long-running rugby concussion group litigation has been pulled back from collapse after an eleventh-hour £1.5m payment satisfied a court-ordered costs liability owed to World Rugby and the Rugby Football Union.

As reported by Yahoo Sports, commercial litigation funder Asertis remained in place after the claimants changed law firms, meaning the costs order could be met. Had the payment not been made, the claims of roughly 1,000 former players would have been at risk.

The payment follows a reprieve granted in August, when Senior Master Jeremy Cook handed down a 13,500-word judgment granting relief from sanction in principle after Richard Boardman's Rylands Garth was replaced by KP Law. The claims of Phil Vickery and Steve Thompson had previously been ruled strike-out-worthy. Defendants had sought more than £2.8m in total, with Rugby Union costs assessed at £2.5m across World Rugby, the RFU and the WRU, and 60% ordered on an interim basis.

The litigation is not out of danger. Some 377 claimants still face automatic dismissal unless medical records are provided by the end of the month.

The episode is a clear illustration of a funder's role beyond case capital. Where a claimant group incurs an adverse costs order mid-proceeding, the funder's willingness to stand behind it determines whether the litigation continues at all. Asertis's decision to remain committed through a change of solicitor preserved a case begun in 2022.

UFC Fighters Resist Discovery Into Who Is Funding Their Wage-Fixing Case

Mixed martial arts fighters suing the UFC over alleged wage suppression are pushing back against the organisation's effort to obtain information about the litigation funding behind their case, characterising the request as a distraction from the merits of the antitrust claims.

As reported by Law360, the fighters' opposition follows the UFC's move earlier this month to press a Nevada federal judge to pull back the curtain on who is financing the proceedings. The dispute arises in Johnson et al v. Zuffa, LLC et al, No. 2:21-cv-01189, in the U.S. District Court for the District of Nevada. The October 15 report was written by Alex Lawson.

The case was filed in June 2021 by Kajan Johnson and C.B. Dollaway against Zuffa and Endeavor Group Holdings, and covers fighters competing from 2017 onward. It is the successor to Le v. Zuffa, which settled for $375 million covering bouts between December 2010 and June 2017 and received final approval from Judge Richard F. Boulware in February 2025 without any accompanying changes to the UFC's business practices.

Funding discovery has become a standard defence tactic in large antitrust and class proceedings, and the fighters' objection tracks arguments made by claimants elsewhere: that the identity of a funder is irrelevant to liability. The case has already generated other discovery friction, including a sanctions motion in February over alleged evidence destruction.